Catalyst Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Catalyst Pharmaceuticals
CPRX Stock  USD 22.40  0.40  1.75%   
Catalyst Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Catalyst Pharmaceuticals' valuation are provided below:
Gross Profit
480.7 M
Profit Margin
0.3763
Market Capitalization
2.8 B
Enterprise Value Revenue
3.6586
Revenue
578.2 M
We have found one hundred twenty available fundamental signals for Catalyst Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Catalyst Pharmaceuticals prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.7 B in 2026. Enterprise Value is likely to rise to about 1.6 B in 2026

Catalyst Pharmaceuticals Total Revenue

593.77 Million

Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 358.2 M or Operating Income of 235.6 M, as well as many indicators such as Price To Sales Ratio of 5.49, Dividend Yield of 0.0 or PTB Ratio of 3.71. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Catalyst Stock
Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Catalyst Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1 B979.1 M269.8 M
Slightly volatile
Total Stockholder Equity878.6 M836.8 M229.2 M
Slightly volatile
Cash624.9 M595.2 M158.8 M
Slightly volatile
Other Assets1.091.154.4 M
Pretty Stable
Cash And Short Term Investments624.9 M595.2 M171.8 M
Slightly volatile
Common Stock Shares Outstanding150.9 M143.7 M87.1 M
Slightly volatile
Liabilities And Stockholders Equity1 B979.1 M269.8 M
Slightly volatile
Other Stockholder Equity534.1 M508.6 M215.6 M
Slightly volatile
Total Liabilities149.5 M142.3 M40.6 M
Slightly volatile
Total Current Assets753 M717.2 M202.9 M
Slightly volatile
Other Current Liabilities124.1 M118.2 M31.1 M
Slightly volatile
Total Current Liabilities145.7 M138.8 M37.8 M
Slightly volatile
Property Plant And Equipment Net4.3 M4.1 M1.5 M
Slightly volatile
Accounts Payable20 M19.1 M5.7 M
Slightly volatile
Non Current Assets Total275.1 M262 M67 M
Slightly volatile
Common Stock Total Equity66.6 K120.8 K82.5 K
Slightly volatile
Property Plant And Equipment Gross5.7 M5.4 M1.8 M
Slightly volatile
Common Stock72.2 K139.2 K85 K
Slightly volatile
Property Plant Equipment1 M974 K582.7 K
Slightly volatile
Other Current Assets25.4 M24.2 M6.9 M
Slightly volatile
Net Receivables79.1 M75.3 M21.4 M
Slightly volatile
Other Liabilities17 M16.2 M7.4 M
Slightly volatile
Non Current Liabilities Total2.7 M3.6 M3 M
Slightly volatile
Net Tangible Assets323.5 M308.1 M129.7 M
Slightly volatile
Capital Surpluse169.1 M288 M172 M
Slightly volatile
Non Current Liabilities Other344.1 K362.2 K2.2 M
Pretty Stable
Current Deferred Revenue796.4 K838.4 K3.9 M
Pretty Stable
Net Invested Capital878.6 M836.8 M252.6 M
Slightly volatile
Net Working Capital607.3 M578.4 M187.9 M
Slightly volatile
Capital Stock117.2 K139.2 K107.3 K
Slightly volatile
Short and Long Term Debt Total2.9 M3.7 M1.8 M
Slightly volatile
Capital Lease Obligations2.8 M3.7 M1.8 M
Slightly volatile
Short Term Debt320 K462.3 K307.8 K
Slightly volatile

Catalyst Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses358.2 M341.1 M105.1 M
Slightly volatile
Research Development13.9 M14.5 M16.8 M
Slightly volatile
Total Operating Expenses275 M261.9 M83.3 M
Slightly volatile
Depreciation And Amortization45.6 M43.4 M9.6 M
Slightly volatile
Selling General Administrative202.5 M192.9 M45.4 M
Slightly volatile
Interest Income1.9 M1.8 M924.2 K
Slightly volatile
Net Interest Income19.4 M18.5 M4.6 M
Slightly volatile
Reconciled Depreciation45.6 M43.4 M9.1 M
Slightly volatile
Selling And Marketing Expenses10.9 M11.5 M13.6 M
Slightly volatile

Catalyst Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow166.2 M158.3 M76 M
Slightly volatile
Depreciation45.6 M43.4 M9.6 M
Slightly volatile
Capital Expenditures607.4 K639.4 K5 M
Pretty Stable
End Period Cash Flow624.9 M595.2 M158.8 M
Slightly volatile
Stock Based Compensation26.9 M25.6 M7.4 M
Slightly volatile
Net Borrowings4 M4.5 M4.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.495.78190
Slightly volatile
PTB Ratio3.713.9122.5937
Slightly volatile
Days Sales Outstanding45.4955.8940.6816
Pretty Stable
Book Value Per Share5.85.531.9304
Slightly volatile
Average Payables4 M3.8 M2.7 M
Slightly volatile
Stock Based Compensation To Revenue0.04940.0523.4167
Slightly volatile
Capex To Depreciation0.01610.01691.8658
Pretty Stable
PB Ratio3.713.9122.5937
Slightly volatile
EV To Sales4.354.58173
Slightly volatile
Inventory Turnover3.854.05190
Slightly volatile
Days Of Inventory On Hand59.8593.2440.2926
Slightly volatile
Payables Turnover3.413.732.9327
Slightly volatile
Sales General And Administrative To Revenue0.370.3915.3264
Slightly volatile
Research And Ddevelopement To Revenue0.02810.029619.0752
Slightly volatile
Capex To Revenue0.0010.0010.1169
Pretty Stable
Cash Per Share4.133.931.495
Slightly volatile
Days Payables Outstanding96.111018.1 K
Slightly volatile
Income Quality0.771.321.0399
Slightly volatile
Intangibles To Total Assets0.180.170.1218
Slightly volatile
Current Ratio5.655.948.6603
Slightly volatile
Tangible Book Value Per Share4.554.341.5832
Slightly volatile
Receivables Turnover10.176.7610.7996
Pretty Stable
Graham Number13.0712.455.1583
Slightly volatile
Shareholders Equity Per Share5.85.531.9304
Slightly volatile
Debt To Equity0.00710.00390.0077
Very volatile
Capex Per Share0.0040.00420.1117
Pretty Stable
Graham Net Net3.613.441.2781
Slightly volatile
Average Receivables7.8 M7.4 M5.8 M
Slightly volatile
Revenue Per Share3.923.741.2472
Slightly volatile
Interest Debt Per Share0.02540.02420.0143
Slightly volatile
Debt To Assets0.00590.00340.0062
Very volatile
Short Term Coverage Ratios477537586
Slightly volatile
Operating Cycle81.3113761.0948
Slightly volatile
Price Book Value Ratio3.713.9122.5937
Slightly volatile
Days Of Payables Outstanding96.111018.1 K
Slightly volatile
Ebt Per Ebit0.81.01.0024
Very volatile
Company Equity Multiplier1.41.351.298
Slightly volatile
Long Term Debt To Capitalization0.010.01050.0098
Slightly volatile
Total Debt To Capitalization0.0070.00390.0076
Very volatile
Debt Equity Ratio0.00710.00390.0077
Very volatile
Quick Ratio5.475.768.5763
Slightly volatile
Net Income Per E B T1.070.870.9604
Very volatile
Cash Ratio4.694.934.7129
Very volatile
Days Of Inventory Outstanding59.8593.2440.2926
Slightly volatile
Days Of Sales Outstanding45.4955.8940.6816
Pretty Stable
Cash Flow Coverage Ratios82.1886.51143
Pretty Stable
Price To Book Ratio3.713.9122.5937
Slightly volatile
Fixed Asset Turnover13712396.8418
Slightly volatile
Debt Ratio0.00590.00340.0062
Very volatile
Cash Flow To Debt Ratio82.1886.51143
Pretty Stable
Price Sales Ratio5.495.78190
Slightly volatile
Asset Turnover0.420.520.3063
Slightly volatile
Price Fair Value3.713.9122.5937
Slightly volatile

Catalyst Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B666.8 M
Slightly volatile
Enterprise Value1.6 B1.5 B586 M
Slightly volatile

Catalyst Fundamental Market Drivers

Forward Price Earnings10.2669
Cash And Short Term Investments517.6 M

Catalyst Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Catalyst Pharmaceuticals Financial Statements

Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue838.4 K796.4 K
Total Revenue565.5 M593.8 M
Cost Of Revenue79.2 M83.1 M
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.39  0.37 
Research And Ddevelopement To Revenue 0.03  0.03 
Revenue Per Share 3.74  3.92 
Ebit Per Revenue 0.36  0.37 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY